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imited access for high-quality bio-
-logics due to cost of treatment con-
stitutes an unmet medical need in the US 
and other regions of the world. The term 
“biosimilar” is used to designate a follow-
on biologic that meets extremely high 
standards for comparability or similar-
ity to the originator biologic drug that is 
approved for use in the same indications. 
Use of biosimilar products has already 
decreased the cost of treatment in many 
regions of the world and now a regula-
tory pathway for approval of these prod-
ucts has been established in the US. The 
Food and Drug Administration (FDA) 
led the world with the regulatory con-
cept of comparability and the European 
Medicines Agency (EMA) was the first to 
apply this to biosimilars. Patents on the 
more complex biologics, especially mono-
clonal antibodies, are now beginning to 
expire and biosimilar versions of these 
important medicines are in development. 
The new Biologics Price Competition 
and Innovation Act (BPCIA) allows the 
FDA to approve biosimilars and allows 
the FDA to lead on the formal designa-
tion of interchangeability of biosimilars 
with their reference products. The FDA’s 
approval of biosimilars is critical to facili-
tating patient access to high-quality bio-
logic medicines and will allow society 
to afford the truly innovative molecules 
currently in the global biopharmaceutical 
industry’s pipeline.
Introduction to the Opportunity 
Represented by Biosimilars  
for ALL Stakeholders
Biologics are medicines made in or isolated 
from living systems. They increasingly use 
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recombinant DNA technology, although 
many important biologics continue to be 
naturally sourced, such as certain child-
hood vaccines and blood products. The 
first recombinant product for human 
use, human insulin (Humulin®), was 
approved in the US in 1982. The number 
of approved recombinant protein thera-
peutics, including monoclonal antibodies 
(mAbs), has expanded considerably, not 
least because these complex products can 
be created to bind unique targets.
Global sales of biologics were $93 bil-
lion in 2009, and these sales are expected 
to continue to grow at least twice as fast as 
those of small molecules. Of this cohort 
of highly successful biologic products, 
mAbs are the largest and fastest growing 
segment. The substantial clinical utility 
and commercial success of these prod-
ucts has convinced large pharmaceuti-
cal companies to engage in the research 
and development (R&D) of biologics. 
Approximately 30% of the pharmaceu-
tical and biotechnology industry R&D 
pipeline is composed of biologics, and 
nearly a third of these are mAb-based.1   
It is anticipated that by 2016, ten of 
the top-selling 20 drugs will be biolog-
ics; of these, seven (Humira®, Avastin®, 
Rituxan®, Herceptin®, Remicade®, Prolia® 
and Lucentis®) are mAbs and one (Enbrel®) 
is a fusion protein containing antibody 
components.
However, the growing success of these 
biologics has been inevitably paralleled 
by the increasing challenge to the ability 
of health care systems worldwide to pay 
for them. The products are highly effec-
tive, life-altering therapies, but they have 
a high unit cost and are often used for 
chronic conditions that require on-going 210  mAbs  Volume 3 Issue 2
designate pre- and post-manufacturing 
change biologics as interchangeable was 
assumed by the FDA under the pre-BPCIA 
Public Health Service Act (PHSA), and 
did not entail legislation.
Comparability was supported by indus-
try, both specifically through the trade 
organization Pharmaceutical Research 
and Manufacturers of America (PhRMA), 
and also more generally by individual 
companies. The concept of comparability 
has been used extensively by sponsors of 
licensed biologic products. It is data-driven 
and the burden remains with the sponsor 
to collect the necessary data to convince 
the FDA of the validity of their chosen 
approach, just as is the case with the initial 
biologic approval. These comparability 
“exercises” rarely entailed clinical trials, 
and they never required switching stud-
ies between pre- and post-change product. 
It has never been suggested that the use 
of comparability puts patients’ well-being 
at risk, even though its use has not been 
entirely without incident.6,7
In Europe, the comparability concept 
was also of great value for all stakehold-
ers, but the European use of the term 
“comparable” was also extended to prod-
ucts from different sponsors as per a 2003 
guideline.8 The EMA (known then as the 
European Medicines Evaluation Agency) 
also participated in the development 
and implementation of the International 
Conference on Harmonization (ICH) 
Tripartite Comparability Guideline,9 even 
though they continue to maintain their 
own EU Comparability Guideline. The 
former only applies to a sponsor making a 
manufacturing change to their own prod-
uct. Nonetheless, with minimal extrapola-
tion the cross-sponsor use of comparability 
became the basis for the EU approach 
to biosimilars and informed their defini-
tion of biosimilarity.10 With the extensive 
experience of regulators and sponsors in 
highly regulated markets, comparability 
is the universal standard for judging inter-
changeability of pre- and post-manufac-
turing changes of any biologic. With the 
development of the biosimilar approval 
pathway, the scientific approach under-
lying interchangeability can be broadly 
applied to an originator product under-
going a manufacturing change or a bio-
similar at initial approval or a biosimilar 
legislation that included the BPCIA. As of 
March 2010, FDA has had the authority 
to review and approve biosimilar prod-
ucts that are judged to be “highly simi-
lar” to the originator reference product. 
Although the terms “highly similar” and 
comparability are used by FDA for differ-
ent purposes, the science underpinning 
the approaches is identical. FDA uses the 
term “comparability” only when referring 
to the comparison of product attributes of 
a biologic when the manufacturing pro-
cess is altered. This can result in changes 
in the biologic molecule. The sponsor 
must show that the pre-change and post-
change products are “comparable.” FDA 
uses the term “highly similar” when refer-
ring to comparisons of an originator ref-
erence product and a biosimilar, although 
the methods and analytical tools used in 
both exercises are identical.
The Science-Based Regulatory 
Concept of “Comparability”  
is Fundamental for All Biologics
With the commercialization and rapid 
uptake of biologic drugs, it became appar-
ent in the 1990s that companies would   
have to scale up their manufactur-
ing process or transfer their processes 
to other manufacturing sites to meet 
demand. These changes in manufactur-
ing can induce changes in the product 
attributes that can have an impact on 
clinical safety and efficacy. To address 
this issue, the FDA and other regula-
tory agencies developed a scientifically 
valid approach to evaluate these products 
pre- and post-manufacturing change. In 
doing so, the FDA originated the term 
“comparability” for head-to-head prod-
uct comparisons of products, as described 
in their 1996 Guidance “Demonstration 
of Comparability of Human Biological 
Products, including Therapeutic 
Biotechnology-derived Products.” 5 If a 
product is judged to be comparable pre- 
and post-manufacturing change, then the 
products resulting from the process before 
and after the change are interchangeable. 
Comparability, as first conceived, was 
a soundly-grounded scientific concept 
and neither statutory history nor relative 
complexity of the product factored into 
the equation. The authority to assess and 
treatment. It is estimated that the aver-
age daily treatment cost for a small mol-
ecule brand drug is around $1 per day 
(with small molecule generic drug costing 
cents per day), whereas that of a branded 
biopharmaceutical is $22 per day. It 
was widely reported in So et al.2 that a 
breast cancer patient’s average cost for 
Herceptin® (trastuzumab) is $37,000, the 
treatment costs for rheumatoid arthritis 
or Crohn disease with Humira® (adalim-
umab) is $50,000 per year, and the cost 
to a Gaucher disease patient for treat-
ment with Cerezyme® (imiglucerase) can 
be $200,000 per year for the rest of their 
life. The top six biologics already consume 
43% of the drug budget for Medicare Part 
B,2 and if the current trend in increasing 
usage continues, expenditure will inevita-
bly also increase. This situation is unsus-
tainable and may lead to limited access 
whereby only the more severely affected 
patients are treated with these agents when 
disability might be prevented or limited 
with earlier intervention. Access for even 
the current patients treated with biologics 
can become restricted due to costs.
The development of high-quality, but 
lower cost, biologics when patents expire 
addresses the need to improve access to 
patients who can benefit from treatment. 
In 2004, legislation enacted in Europe 
created a pathway3 for the approval of 
biosimilar products that has been adapted 
more broadly. The EMA used their 
authority to approve subsequent versions 
of biologic products that explicitly refer to 
a previously approved biologic, based on 
the comparability approach, by approv-
ing Omnitrope® (somatropin) as the first 
biosimilar product available in Europe in 
2006.4
With nearly three decades of experi-
ence with marketed biotech medicines 
in the US, patents on a number of these 
recombinant biologics are beginning to 
expire. It is estimated that off-patent sales 
will represent approximately 40% of the 
anticipated global sales in 2015 and by 
2020, over $100 billion in biologic sales 
will be off patent.
Until 2010, the FDA lacked the legal 
authority to approve biosimilar medi-
cines in the manner that had occurred 
in Europe. This deficit was addressed 
with the passage of healthcare reform www.landesbioscience.com mAbs  211
close enough to the originator molecule 
to be judged biosimilar in analytical or 
clinical testing. Some use these “alterna-
tive” biologics to cast doubt on the clini-
cal utility of true biosimilars. Schellekens 
evaluated several alternative recombinant 
erythropoietins manufactured in Asia and 
demonstrated with isoelectric focusing 
gels that they were not comparable with 
the originator product.15 This is unlike 
approved biosimilars, which are highly 
similar to the originator reference as 
shown by Brockmeyer and Seidl who, also 
using isoelectric focusing gels, compared 
biosimilar erythropoietin to the origina-
tor product.16 Alternative biologics are not 
biosimilar and have not been approved 
as biosimilar, and they should be clearly 
distinguished from approved biosimilars 
in discussions about the new biosimilars 
pathway implemented in the US. The 
FDA is expected to approve biosimilars to 
the same standards as the marketed refer-
ence biologics, given that the same stan-
dards of safety, purity and potency apply. 
Questions about other biologics in other 
jurisdictions that apply lower standards 
are not relevant to the biosimilars debate 
in the US or other highly-regulated mar-
kets, but will likely continue to be invoked 
save substantial time and resources and 
allow FDA to concentrate on defining a 
guideline for interchangeability, which is 
an issue not addressed in Europe as a regu-
latory matter.
The highly-regulated markets have 
specific requirements for biosimilars 
regarding the comparative studies that a 
biosimilar sponsor must conduct to prove 
biosimilarity to their chosen originator 
reference biologic. We have estimated that 
the costs of developing a biosimilar prod-
uct for highly-regulated markets such as 
Europe or the US ranges from $75–250 
million, which will limit the number of 
successful companies in this space.
Developing markets also have compel-
ling unmet medical needs for targeted bio-
logics, which has fostered local regulatory 
processes with reduced requirements, if 
any, for head-to-head studies. Such “non-
highly-regulated” jurisdictions approve 
what we term “alternative biologics.” 
These jurisdictions address the unmet 
medical need by allowing a follow-on bio-
logic for the same target as the originator 
molecule to be approved without a dem-
onstration of biosimilarity. Such products 
may be adequate for the purpose, but 
they are not biosimilars, i.e., they are not 
undergoing a manufacturing change. 
Comparability is already being used for 
post-approval manufacturing changes to 
biosimilars in Europe and elsewhere.
An Overview of Requirements  
for Biosimilars Development
Europe has led in the approval of biosimi-
lars because EMA was the first regula-
tory authority to be given the mandate to 
review and approve biologic products that 
explicitly referred to a previously approved 
product and because patents on key prod-
ucts expired in Europe sooner than in the 
US. Due to successful experiences in the 
EU, use of the EU approach to biosimi-
lars regulation in the US has been advo-
cated,11,12 and the European approach was 
endorsed by a wide variety of the stake-
holders presenting at the recent FDA pub-
lic hearing on this topic.13 This meeting 
sought public input on the implementation 
by the FDA of the new abbreviated bio-
similar pathway created in the BPCIA.14 
However, it is unlikely, despite the many 
recent efforts at harmonizing the regula-
tions in the highly regulated markets, that 
the FDA will adopt the EU biosimilars 
guidelines (Fig. 1) even though it could 
Figure 1. European biosimilar guidelines. The EMA began with an overarching guideline on biosimilars and then general guidelines, before issuing 
product class specific data requirements. The EU Guidelines that have been finalized are indicated in blue. A draft guideline for mAbs is currently avail-
able for public comment.25212  mAbs  Volume 3 Issue 2
EU and US products are “highly similar” 
and are probably manufactured in the 
same plant, (4) the variance induced by 
manufacturing changes establishes “goal 
posts” that a biosimilar company can 
employ for establishing comparability and 
(5) it is apparent that originators are essen-
tially manufacturing biosimilars of their 
original product.18
Once “goal posts” are established for a 
originator reference product, an iterative 
process is used in developing a biosimilar 
where the product is fully evaluated by 
physicochemical and biological character-
ization compared to the originator prod-
uct. When product attributes fall outside 
established “goal posts,” various process 
steps are modified to produce product 
attributes that are within the variability of 
the originator product (Fig. 3). This pro-
cess is repeated until highly similar prod-
uct attributes are achieved. The degree of 
similarity that is established is based on 
analytical characterization that is run in 
parallel with iterative process development 
activities.
Depending on the extent that product 
attributes of the biosimilar overlap with 
those of the originator product, preclinical 
and clinical development can be abbrevi-
ated compared to developing a novel 
biologic. An abbreviated development 
program is justified when the biosimi-
lar product attributes are highly similar 
to the originator product. As a historical 
perspective, when evaluating manufac-
turing changes, FDA has rarely required 
sponsors to repeat preclinical or clinical 
studies,19,20 but for biosimilars such stud-
ies are currently expected in both the EU 
and US. The authority is given to the FDA 
in BPCIA to waive preclinical and clinical 
studies, yet it is clear that they will be con-
servative and not waive such requirements 
in the near future.
Once a biosimilar candidate is shown 
to be “highly similar” (also a BPCIA 
statutory requirement), at the analyti-
cal level and through biological charac-
terization, the subsequent pre-clinical 
and clinical studies can be streamlined 
as a scientific matter. However, if any of 
the product attributes of the proposed 
biosimilar deviate from those of the ref-
erence product, then scientific justifica-
tion of presumed safety/efficacy impact 
product (biosimilar) may be substituted 
for the reference product without the 
intervention of the health care provider 
who prescribed the reference product”]. 
An application for interchangeability can 
be concurrent or subsequent to the appli-
cation for a biosimilar product under   
351(k) of the BPCIA.
As discussed previously, originator bio-
logic products undergo changes over time, 
e.g., when the manufacturing process is 
modified by scaling up or transferred to 
alternate facilities. Such changes in the 
originator product attributes provide a 
distribution of these attributes that should 
be considered acceptable because the 
products were subsequently administered 
to patients successfully. The limits to this 
distribution of product attributes are what 
we call “goal posts,” and these can be used 
to evaluate the acceptability of a biosimi-
lar. If the product attributes fall within   
the variability of the originator molecule 
after manufacturing change, then the 
biosimilar should be considered “highly 
similar.” The foundational principle and 
goal for the development of biosimilars at 
Sandoz has been to achieve a high degree 
of similarity to the originator reference 
product such that our biosimilar is as 
similar to the originator product as the 
originator product is to itself considering 
the variability induced by manufactur-
ing changes. As an example of establish-
ing these goal posts, Figure 2 plots one 
specific glycan structure in a commercial 
mAb followed in many batches over a four 
year period. Both US and EU commercial 
formulations were analyzed over time at 
Sandoz using state of the art technologies 
for this specific glycan structure. There 
is very little variability between batches 
over time when using the same manufac-
turing process. However, a major shift in 
this product attribute does occur with a 
manufacturing change wherein the rela-
tive amount of this structure drops from 
approximately 50–30%. This change was 
first seen with European product, but 
eventually the same product attribute was 
seen with US commercial product. This 
figure confirms several points: (1) batch 
to batch variability is small during rou-
tine manufacturing, (2) major shifts in 
product attributes may occur as a result 
of manufacturing changes, (3) in this case 
by some to confuse or frighten patients or 
providers.
Likewise, Europe has expressed con-
fidence in the quality and consistency 
of its biologic products, including bio-
similars. At the 2008 European Generics 
Medicines Association Biosimilars 
Symposium, Nicolas Rossignol, for-
mer administrator of the European 
Commission Pharmaceuticals Unit, said 
that “biosimilar products approved by the 
European Commission in accordance with 
EMEA guidelines should not be subject 
to unfounded questions regarding their 
safety” and “a biosimilar product is as safe 
and efficacious as any other product autho-
rized by the European Commission in the 
EU.”17
In order to develop a biosimilar, a spon-
sor must necessarily ensure quality, plus 
safety and efficacy (EU) or safety, purity 
and potency (US), and it must be biosimi-
lar to the reference product. However, in 
order to be viable as a business, a sponsor 
must also ensure their development is effi-
cient by receiving product approval in a 
timely manner and with lower costs than 
those required for development of a novel 
agent. This combination will allow com-
petitive pricing, improved access and an 
appropriate return on investment. Thus, 
the key to biosimilar development is the 
demonstration of a high degree of molecu-
lar similarity, as well as adequate safety and 
efficacy data to achieve commercial viabil-
ity (represented by a broad product label).
If an originator biologic product has 
multiple indications, extrapolation to 
additional indications for a biosimilar, 
based on solid biosimilar data in a sensi-
tive indication, may be granted in the EU. 
This is appropriate where comparability 
is shown, clinical data supports equiva-
lent safety and efficacy to the originator 
molecule in at least one indication, and a 
common mechanism of action can be pre-
sumed for the clinical effect.
Defining the “Goal Posts”:  
Product Attribute Distribution  
of Originator Product
In the US, the BPCIA is unique in allow-
ing the FDA to designate a biosimilar as 
interchangeable with its reference product 
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on the degree to which FDA is driven by 
this scientific justification for an abbre-
viated clinical development program, as 
comparability in the context of a manu-
facturing change. Sponsors’ use of the 
new US biosimilars pathway will depend 
is required or additional pre-clinical and 
clinical data demonstrating similarity, are 
needed, just as is the case for the use of 
Figure 2. Analyzing complex product attributes over time. The bG2 glycan structure was quantified by Sandoz in many batches of commercial 
product distributed by the originator in the EU (light blue) and the US (dark blue). Expiry date of the product batches is listed on the x-axis and relative 
amount of product attribute enrichment is listed on the y-axis. Pre-shift quality refers to the content of the attribute prior to a manufacturing change 
and post-shift quality after the manufacturing change.
Figure 3. Biosimilar development process. The development of a biosimilar relies on creation of a design space based on analysis of the reference 
product and then iterative development of a biosimilar to fit the chosen specifications. There is no access to, nor need for, originator data at any point 
in this process. The early process development is essential, and later development cannot compensate for this initial generation of a “highly similar” 
candidate product. As the complexity of the reference product increases, the initial development becomes more challenging, and the likelihood that 
multiple iterations will be needed increases.214  mAbs  Volume 3 Issue 2
the “goal posts” will have to be defended 
or demonstrated not to alter the clinical 
outcomes of the product. Thus, preclinical 
and clinical study designs will be tailored 
to the comprehensive comparability data 
generated analytically.
While the US is generally behind the 
EU with regard to biosimilars, two prod-
ucts are worth mentioning as examples of 
FDA experience using the science appropri-
ately within their prior regulatory author-
ity. Most biologics are regulated under 
the PHSA. For historical reasons, a few 
biologics are regulated under the Federal 
Food, Drug and Cosmetic Act, and there-
fore the Hatch Waxman generic pathways 
are available for these products, which 
include somatropin and enoxaparin. In 
May 2006, Sandoz achieved an approval 
for Omnitrope® (somatropin) based on a 
demonstration of “high similarity”22/com-
parability to Pfizer’s Genotropin® (soma-
tropin), and in July 2010, the approval of 
enoxaparin as a fully substitutable generic 
to Sanofi-Aventis’ Lovenox® (enoxaparin). 
While the statutes within the BPCI and 
Hatch Waxman legislation differ, many of 
the same scientific and regulatory consid-
erations apply, not least because the latter 
represents a naturally-sourced complex 
mixture that was appropriately charac-
terized as part of the application and no 
clinical trials were required. In review-
ing the enoxaparin file, FDA established 
five criteria to determine “sameness” of 
Sandoz enoxaparin to Lovenox® (Fig. 5). 
These included physiochemical properties, 
source material, the sugar building blocks, 
Most biologics that will become refer-
ence products for future biosimilar devel-
opment have undergone comparability 
exercises over their lifetimes during scale-
up activities to meet demand. Even though 
these manufacturing changes are tightly 
regulated, they are still associated with 
observable changes in the product attri-
butes over time. However, by remaining 
on the market with the same label during 
these times, regulators are indicating that 
each of these pre- and post-manufacturing 
change products is interchangeable with 
itself. This regulatory scientific approach 
can be used to evaluate and approve bio-
similar candidates with attributes falling 
between the goal posts of reference prod-
ucts that would be considered highly simi-
lar to the originator (“highly similar” is 
the term used in BPCIA and ICH Q5E). 
If judged highly similar and shown to pro-
duce equivalent clinical responses after 
switching with the originator, the sponsor 
should receive approval as interchangeable 
with the reference product (Figs. 4 and 5). 
Such an approach by sponsors and regula-
tors is consistent with all prior regulatory 
decisions regarding major manufacturing 
changes of originator products.
Like the use of comparability to make 
manufacturing changes, the type and 
extent of preclinical and clinical studies 
will be governed by how well the biosimi-
lar sponsor can keep their product within 
the bounds defined by the “goal posts” of 
the reference product. It is not trivial to 
achieve overlapping product attributes, 
and any differences that are not within 
opposed to their endorsement of a pre-
cautionary approach that requires many 
of the typical development steps of a the 
traditional novel biologic 351(a) biologics 
license application.
To achieve highly similar product 
attributes, the “goal posts” chosen by the 
biosimilar sponsor, which represent vari-
ability of originator product attributes 
for their design space,21 become key to 
the development of a 351(k) biosimilar. 
The “goal posts” for biosimilarity are 
established through an examination of 
the reference product attributes by the 
biosimilar sponsor by obtaining com-
mercial reference product and analyzing 
product characteristics, and not through 
access to the originators data (Fig. 4). 
The “goal posts” approach is dependent 
upon analysis of multiple batches of refer-
ence product manufactured in the recent 
past, but also, to the extent possible, over 
an extended period of time since its initial 
approval, including batches pre- and post-
manufacturing change. Hence, sample 
collection and evaluation of commercial 
drug of the chosen originator reference 
product is a critical part of the planning 
for the development of a biosimilar. “Goal 
posts” of originator product attributes are 
only broadened if the reference product 
sponsor changes their product’s specifica-
tions after manufacturing changes even 
if such changes occur toward the end 
of their patent life in anticipation of life 
cycle management or to block biosimilar 
competition.
Figure 4. Biosimilarity goal posts. The “goal posts” of biosimilarity are established by the biosimilar sponsor by their analysis of the distribution of 
product attributes present in the reference product pre- and post-manufacturing change. They then use these to select the design space for their 
biosimilar candidate. While the complete quality range may be quite broad for the life time of the reference product, the biosimilar sponsor will select 
a tighter range of control for their biosimilar product.www.landesbioscience.com mAbs  215
The data showing that, for example, an 
EU reference product and a US refer-
ence product are indistinguishable should 
obviate the need for a repetition of critical 
studies. If originators can prepare global 
data sets and dossiers, but biosimilar spon-
sors cannot, this will have a major impact 
on the supply of the respective products, 
and the consequent access by patients. 
Scientific principles suggest that using a 
single global reference product is reason-
able, provided that it is proven comparable 
to the same product labeled in other major 
regions.
Interchangeability or Substitution
The one explicit authority granted to the 
FDA, and not available to EMA, is that 
they can designate a biosimilar as inter-
changeable with its reference originator 
product. Interchangeability, as defined in 
the BPCIA, allows a pharmacist to sub-
stitute an interchangeable biosimilar with 
the originator drug without the interven-
tion of the original prescribing physi-
cian. Such a designation would enhance 
adoption of biosimilars and more rapidly 
enable costs savings and increased access, 
just as is the case today with traditional 
generic drugs. FDA can lead the world in 
establishing criteria for an interchangeable 
designation, but even this, as discussed 
regions and countries, intellectual proper-
ties rights differ, and the regulatory policy 
by which medicines first reach the market 
can be extremely specific. For potential 
sponsors of all biologics, including bio-
similars, considerations must include the 
research and development costs of the reg-
ulatorily-required studies. Regional regu-
latory authorities now generally require 
biosimilar sponsors to compare their bio-
similar to the reference product approved 
in the local region. That is, when per-
forming studies in Europe, EMA gener-
ally requires use of a European-labeled 
reference product as a comparator, while 
a US-labeled reference product would be 
necessary as a comparator for approval 
in the US. Thus these policies currently 
require essentially a duplicative clini-
cal development program, which vastly 
increases development costs. To date, each 
law in each country has defaulted to the 
need for a reference product previously 
approved by that regulatory authority. 
This is the case even if the biologic drug 
used as a reference is made by a single 
facility for worldwide use, and the only 
difference in the product in each country 
is the label. Presently, it is the label on the 
product that defines its regulatory status, 
and not what is in the tube. Thus, there is 
a need for scientifically-appropriate bridg-
ing to be accepted across jurisdictions. 
biologic assays and in-vitro pharmacody-
namic profile. Each of these criteria had 
to be comparable for FDA to rule that the 
two products were the “same”. In this case, 
the analytical characterization, along with 
other information, provided sufficient data 
for FDA to approve the product. Again, 
enoxaparin was not approved as a biosimi-
lar under the new BPCIA pathway, but the 
scientific approach used by FDA is equally 
applicable.
The Need for a “Global”  
Biosimilar Pathway
Biosimilars are now recognized around 
the world as safe and effective medicines, 
and the World Health Organization has 
also generated guidelines23 to assist the 
less highly regulated markets in their con-
sideration of applications from biosimilar 
sponsors. The standards are largely derived 
from those demonstrated to be success-
fully applied in the EU, and other regu-
lated markets such as Australia, Canada 
and Japan.
The need for access to high quality, safe 
and effective biologics is global, as is the 
regulatory science, and increasingly, the 
biomanufacturing experiences. However, 
healthcare priorities and resources, as 
reflected in infrastructure and payment 
for medicines, vary between individual 
Figure 5. The one US marketed generic biologic: enoxaparin. Generic enoxaparin was approved by FDA on July 23, 2010. Although not a “biosimilar” 
insofar as it was not approved through the new biosimilar 351(k) regulatory pathway, scientifically it is a fully interchangeable generic biologic and 
many of the FDA considerations anticipated for biosimilars s apply.216  mAbs  Volume 3 Issue 2
8. EU Guideline on Comparability of Medicinal 
Products containing Biotechnology-derived Proteins 
as Active Substances: Quality issues (CPMP 
December 2003). www.emea.europa.eu/pdfs/
human/bwp/320700en.pdf
9.  ICH Q5E: Comparability of Biotechnological/
Biological Products Subject to Changes in Their 
Manufacturing Process. EU: Adopted by CMPM, 
December 1, 2004, CPMP/ICH/5721/03, date 
for coming into operation: June 2005; MHLW: 
Adopted 26 April 2005, PFSB/ELD Notification No. 
0426001; FDA: Published in the Federal Register, 
Vol. 70, No. 125, June 30, 2005; 37861-2. www.
ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q5E/Step4/Q5E_Guideline.
pdf
10. Directive 2004/27/EC of the European Parliament 
and of The Council of 31 March 2004 amending 
Directive 2001/83/EC on the Community code 
relating to medicinal products for human use. http://
eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=O
J:L:2004:136:0034:0057:EN:PDF
11. Senate HELP Full Committee Hearing “Follow-On 
Biologics” March 8, 2007; http://help.senate.gov/
hearings/hearing/?id = 0d7fdce8-b5cd-5a56-8930-
31dfb58e7c11.
12.  FDA Public Hearing on Approval Pathway 
for Biosimilar and Interchangeable Biological 
Products, 11/3/2010 Transcript Document ID: 
FDA-2010-N-0477-012. www.regulations.gov/
search/Regs/home.html#documentDetail?R = 
0900006480bafe46.
13.  Federal register notice Food and Drug Administration 
[Docket No. FDA-2010-N-0477] Approval Pathway 
for Biosimilar and Interchangeable Biological 
Products; Public Hearing; Request for Comments. 
http://edocket.access.gpo.gov/2010/pdf/2010-
24853.pdf
14. Biologics Price Competition and Innovation Act 
(BPCIA) provisions of the Patient Protection and 
Affordable Care Act (PPACA). http://frwebgate.
access.gpo.gov/cgi-bin/getdoc.cgi?dbname = 111_
cong_bills&docid=f:h3590enr.txt.pdf
15.  Schellekens H. Biosimilar epoetins: How similar are 
they? Eur J Hosp Pharm 2004; 10:243-7.
16.  Brockmeyer C, Seidl A. Binocrit: assessment of qual-
ity, safety and efficacy of biopharmaceuticals. Eur J 
Hosp Pharm Prac 2009; 15:34-40.
17. European Generics Medicines Association. EGA 
Conference Highlights: 6th European Generics 
Medicines Association Biosimilars Symposium 
2008. www.egagenerics.com/doc/ega_high-
lights_2008_02.pdf
18. Novartis submission to FDA-2010-N-0477 docket 
on Notice: Approval Pathway for Biosimilar and 
Interchangeable Biological Products; Hearing. 
www.regulations.gov/#!documentDetail;D=FDA-
2010-N-0477-064.1.
19. Assessing the Impact of a Safe and Equitable 
Biosimilar Policy in the United States. Statement of 
Janet Woodcock MD, Deputy Commissioner, Chief 
Medical Officer, Food and Drug Administration 
before the Subcommittee on Health, House 
Committee on Energy and Commerce May 2, 2007. 
www.fda.gov/NewsEvents/Testimony/ucm154017.
htm
20.  Follow-on Protein Products. Statement of Janet 
Woodcock MD, Deputy Commissioner, Chief 
Medical Officer Food and Drug Administration 
before the House Committee on Oversight and 
Government Reform, March 26, 2007. www.fda.gov/
NewsEvents/Testimony/ucm154070.htm
Comparability applies to complex prod-
ucts such as mAbs just as it does to other 
smaller and simpler biologics. By engaging 
today in advocating and implementing the 
highly similar standard for mAb biosimi-
lars and working with EU on their pub-
lished draft guidelines, the FDA can rejoin 
EMA in leading the oversight of all bio-
logics for a global patient need. The FDA 
engagement in the creation of the new 
regulatory approaches for interchangeable 
biologics, originator and biosimilar, based 
on their original insights with comparabil-
ity, gives the FDA additional opportunity 
for leadership.
Note 
This paper is based on presentations 
given by Mark McCamish on November 
30, 2010 at the 6th European Antibody 
Congress in Geneva, Switzerland;24 on 
December 8, 2010 at IBC’s 8th Annual 
International Conference on Antibody 
Therapeutics held in San Diego, CA and 
also on the presentation and submission 
made by the Novartis Group of companies 
to the FDA Docket on Approval Pathway 
for Biosimilar and Interchangeable 
Biological Products.18
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Appendix
Definitions.  Biosimilar, PHSA 351(k) 
application (US) or “similar biologi-
cal medicinal products” (EU); BPCIA, 
Biologics Price Competition and 
Innovation Act, the biosimilars pro-
visions of the US health care reform 
statute under which most drugs have been 
approved in the US; PHSA, Public Health 
Service Act, the statute under which most 
biologics have been licensed (approved) in 
the US.